London-based Lumendi received 510(k) clearance from the FDA for its DiLumen, an endoscopic accessory.
Laval, Quebec-based Valeant Pharmaceuticals made a series of leadership moves adding one executive and losing three others.
New York-based Synergy Pharmaceuticals released results from the first of two phase III clinical trials evaluating the safety and efficacy of plecanatide, its irritable bowel syndrome treatment.
Madison, Wis.-based Exact Sciences Corp. agreed to a contract with Louisville, Ky.-based Humana to cover its Cologuard colon cancer screening test as an in-network service.
More articles on gastroenterology and endoscopy:
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis
ASGE comments on 21st Century Cures Act: 3 notes
IBD monitoring index may pave the way for GI mobile health: 3 study insights
